Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis

Immunoglobulin light-chain (AL) amyloidosis is a rare, incurable plasma cell disorder. Its therapy has benefited immensely from the expanding drug armamentarium available for multiple myeloma. Pomalidomide in combination with weekly dexamethasone (Pom/dex) is active among patients with relapsed myel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dispenzieri, Angela, Buadi, Francis, Laumann, Kristina, LaPlant, Betsy, Hayman, Suzanne R., Kumar, Shaji K., Dingli, David, Zeldenrust, Steven R., Mikhael, Joseph R., Hall, Robert, Rajkumar, S. Vincent, Reeder, Craig, Fonseca, Rafael, Bergsagel, P. Lief, Stewart, A. Keith, Roy, Vivek, Witzig, Thomas E., Lust, John A., Russell, Stephen J., Gertz, Morie A., Lacy, Martha Q.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2012
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3369677/
https://ncbi.nlm.nih.gov/pubmed/22493299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-02-413161
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados